Cyclophosphamide as a first-line therapy in LGL leukemia

被引：80

作者：

Moignet, A. ^{[1
]}

Hasanali, Z. ^{[2
]}

Zambello, R. ^{[3
]}

Pavan, L. ^{[3
]}

Bareau, B. ^{[4
]}

Tournilhac, O. ^{[5
]}

Roussel, M. ^{[6
]}

Fest, T. ^{[6
,8
]}

Awwad, A. ^{[2
]}

Baab, K. ^{[2
]}

Semenzato, G. ^{[3
]}

Houot, R. ^{[1
,7
,8
]}

Loughran, T. P., Jr. ^{[2
]}

Lamy, T. ^{[1
,7
,8
]}

机构：

[1] Rennes Univ Hosp, Dept Clin Hematol, Rennes, France

[2] Penn State Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA

[3] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy

[4] Clin Cesson Sevigne Rennes, Rennes, France

[5] Hop Estaing, Dept Clin Hematol, Clermont Ferrand, France

[6] Rennes Univ Hosp, Hematol Immunol & Cell Therapy Dept, Rennes, France

[7] INSERM, CIC 0203, F-75654 Paris 13, France

[8] Univ Rennes 1, Rennes, France

来源：

LEUKEMIA | 2014年 / 28卷 / 05期

关键词：

GRANULAR LYMPHOCYTE LEUKEMIA; RED-CELL APLASIA; STAT3; MUTATIONS; LYMPHOPROLIFERATIVE DISEASE; COHORT;

D O I：

10.1038/leu.2013.359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1134 / 1136

页数：4

共 50 条

[11] First-line therapy of chronic myeloid leukemia - focus on dasatinib
Amrein, Philip C.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2012, 2 : 77 - 85
[12] Nilotinib and Dasatinib in the First-Line Therapy for chronic myeloid Leukemia
Pretscher, Dominik
Wilhelm, Martin
MEDIZINISCHE KLINIK, 2010, 105 (08) : 588 - 588
[13] First-line therapy
Einsele, H.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 113 - 113
[14] FIRST-LINE THERAPY
Kosmidis, P. A.
LUNG CANCER, 2009, 64 : S12 - S13
[15] Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia
Bouvet, Emmanuelle
Borel, Cecile
Oberic, Lucie
Compaci, Gisele
Cazin, Bruno
Michallet, Anne-Sophie
Laurent, Guy
Ysebaert, Loic
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2013, 98 (01): : 65 - 70
[16] A first for first-line therapy in NSCLC
Rebecca Kirk
Nature Reviews Clinical Oncology, 2011, 8 (12) : 691 - 691
[17] Hypomethylating agents as first-line therapy in acute myeloid leukemia (AML).
Bailey, Samuel D.
Gul, Zartash
Slone, Stacey A.
Van Meter, Emily Marie
Lawson, Amber
Raufi, Ali
Hayslip, John W.
Monohan, Gregory
Howard, Dianna S.
McDonagh, Kevin T.
Alkadhimi, Zaid
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[18] Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Hillmen, Peter
Skotnicki, Aleksander B.
Robak, Tadeusz
Jaksic, Branimir
Dmoszynska, Anna
Wu, Jingyang
Sirard, Cynthia
Mayer, Jiri
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5616 - 5623
[19] Debate: What Is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?
Shadman, Mazyar
Stephens, Deborah M.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 993 - 997
[20] First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment
Bauduer, Frederic
PRESSE MEDICALE, 2009, 38 (01): : 140 - 142

← 1 2 3 4 5 →